Lead program: Preclinical

Transneural Therapeutics

Data updated June 27, 2026

2 Drug Candidates

Transneural Therapeutics is a Washington-based preclinical biotech spun out from CaaMTech in April 2025, developing AI-engineered non-hallucinogenic neuroplastogens for neuropsychiatric disorders. Lead candidate TN-001 is a dual 5-HT2A partial agonist/5-HT2B antagonist designed to deliver rapid antidepressant efficacy without hallucinations, potentially enabling outpatient dosing. TN-001 is in IND-enabling studies for MDD and PTSD, with preclinical data presented at ACNP 2026. CEO Charmaine Lykins brings experience from Karuna, ACADIA, and MapLight.

Pipeline Intelligence

Developer Momentum

Programme tracker

Active candidates: 2
Active programmes: 2
Lead stage: Preclinical
Forecast coverage: 2 of 2

Latest sourced update

Transneural Therapeutics — Website

Jun 27, 2026 - company-website - Transneural Therapeutics - TN-001 (5-HT2A Partial Agonist / 5-HT2B Antagonist)

Next known catalyst

Regulatory filing submitted

Timing not specified - TN-001 (5-HT2A Partial Agonist / 5-HT2B Antagonist) / TN-001 — IND-enabling MDD/PTSD - Confidence: 40%

9 sources0 pipeline-linked trials0 pipeline-linked papers1 Preclinical1 Discovery

Development Programmes

TN-001 (5-HT2A Partial Agonist / 5-HT2B Antagonist)

Preclinical

Major Depressive Disorder (MDD)PTSD

Non-hallucinogenic neuroplastogen with dual 5-HT2A partial agonist / 5-HT2B antagonist mechanism. AI-engineered scaffold from CaaMTech IP. IND-enabling. ACNP 2026 poster: dose-dependent synaptogenesis in rat neuronal cultures, antidepressant phenotype in forced swim, no head-twitch response, no locomotor impairment.

Programme Tracker

Major Depressive Disorder (MDD)

Primary: US (FDA)

Pre-clinicalActive

Forecast

Regulatory filing submitted

IND-enabling studies. ACNP 2026 preclinical data presented. CEO Lykins states wrapping up preclinical efforts and progressing into clinical trials. IND filing timeline not publicly disclosed.

Milestones

Company milestone

Completed

Actual: Apr 22, 2025

Transneural Therapeutics spun out of CaaMTech to develop non-hallucinogenic neuroplastogens. CEO: Charmaine Lykins (30+ years CNS pharma; CCO at Karuna/BMS, CMO at ACADIA; launched COBENFY, NUPLAZID, REXULTI, LATUDA, CYMBALTA, ZYPREXA).

Why it matters: Dedicated company with best-in-class CNS leadership. Lykins' track record of 10 CNS product launches including recent Karuna/BMS COBENFY gives Transneural credibility for regulatory execution. CaaMTech retains hallucinogenic pipeline (CT-4201) while Transneural gets non-hallucinogenic neuroplastogens.

CaaMTech Spins Out Transneural Therapeutics to Develop Novel Neuroplastogens(Press release)[Verified]

Company milestone

Completed

Actual: Apr 29, 2025

Mark A. Demitrack, MD appointed Chief R&D Officer. 30+ years neuropsychiatry; former CMO at Trevena and Neuronetics (led NeuroStar TMS launch); led Cymbalta NDA at Eli Lilly; 100+ publications; Fellow of APA, member ACNP.

Why it matters: Demitrack's NDA experience (Cymbalta, one of the world's top-selling antidepressants) is exactly the regulatory profile needed to take TN-001 from IND through Phase 3. His ACNP membership provides direct access to the clinical trial investigator network.

Transneural Appoints Mark Demitrack as Chief R&D Officer(Press release)[Verified]

Efficacy data

Completed

Actual: Jan 14, 2026

Preclinical data presented at ACNP 2026 (Nassau, Bahamas): (1) In vitro — TN-001 induces statistically significant dose-dependent structural neuroplasticity in rat neuronal cultures: increased neuron count, synapse formation, and neurite network expansion. (2) In vivo (efficacy) — reduced immobility in forced swim test (antidepressant phenotype). (3) In vivo (safety) — no head-twitch response (absent hallucinogenic properties), no locomotor impairment at therapeutic doses.

Why it matters: Comprehensive preclinical package demonstrates the triple differentiation: neuroplasticity (efficacy), antidepressant phenotype (behavioral), and safety (non-hallucinogenic, no motor impairment). 5-HT2B antagonism specifically mitigates cardiac valvulopathy risk — a concern with chronic serotonergic compounds like fenfluramine. This data package is core to the IND filing.

Transneural Presents Preclinical Data on TN-001 at ACNP 2026(Press release)[Verified]Transneural TN-001 ACNP Poster — Company Website(company-website)[Verified]

Recorded Events

Jan 14, 2026: Efficacy data

Apr 29, 2025: Company milestone

Apr 22, 2025: Company milestone

Evidence Links

Transneural Therapeutics — Website

company-website - Transneural Therapeutics - Jun 27, 2026 - Verified

Neuroplastogens: The Growing Field of Safer Psychedelic Alternatives

industry-media - Labiotech - Jun 27, 2025 - Verified

Undisclosed Programme 2

Discovery

Major Depressive Disorder (MDD)

One of 2 additional undisclosed neuroplastogen programmes. Company website lists 3 total programmes (TN-001 + 2 others). Targets neuropsychiatric and/or neurodegenerative indications.

Programme Tracker

Major Depressive Disorder (MDD)

Primary: US (FDA)

DiscoveryActive

Forecast

Discovery completed

Undisclosed second programme in Transneural broader small-molecule neuroplastogen pipeline. Public materials confirm two additional programmes beyond TN-001, but mechanism, candidate name, and indication remain undisclosed.

Milestones

Discovery started

Completed

Actual: Apr 22, 2025

Transneural launched publicly with a robust preclinical pipeline of non-hallucinogenic neuroplastogens and TN-001 as lead asset.

Why it matters: Supports tracking a second undisclosed programme while keeping it clearly separate from TN-001 and avoiding unsupported mechanism claims.

Watch next: Programme name, target/mechanism disclosure, lead nomination, or IND-enabling update.

Transneural Therapeutics Emerges from Stealth(Press release)[Verified]

Recorded Events

Apr 22, 2025: Discovery started